RSPR Pharma hires Paul de Potocki as Chief Business Officer
Stockholm 2016-08-23
RSPR Pharma AB today announced that Paul de Potocki will join the company as CBO from September 19. Paul will be responsible for business development and commercial planning, including pricing, reimbursement and market access. Paul has solid experience from strategic corporate development, international business negotiations and leadership in public and private multicultural organizations. He was SVP commercial operations at Biovitrum (now SOBI) where he was responsible for several out-licensing deals and CEO of Aerocrine AB, a Swedish public asthma diagnostic device company. “We are thrilled to have Paul on board with his vast experience from business development and commercial operations and especially his background in the asthma business”, says Dr Carl-Johan Dalsgaard, CEO and co-founder of RSPR Pharma.
About RSPR Pharma AB
RSPR Pharma AB is a Swedish private clinical stage company exploring new medical approaches to treat respiratory diseases. The major shareholders are HealthCap (co-founder), Forbion Capital Partners of the Netherlands, and Novo Seeds and Sunstone of Denmark.
About RSPR Pharma’s Phase II Proof of Concept trial in uncontrolled asthma
RSPR Pharma is developing its proprietary lead compound, CRD007, an oral anti-asthmatic that is half-way through a phase II clinical proof of concept trial in patients not fully controlled by inhaled corticosteroids and long acting beta-agonists (ICS/LABA). The study is on track and a randomized, placebo-controlled, double-blind multicenter trial involving up to 200 patients at 22 centers in 4 different countries.
About asthma
Asthma is an inflammatory condition affecting some 300 million people world-wide. Despite the use of gold standard therapy (ICS/LABA), only 50% of asthma patients have acceptable asthma control, and the socioeconomic burden of uncontrolled asthma is huge. CRD007 is intend as an oral add-on therapy for uncontrolled moderate to severe asthma before considering injectable therapy.
MEDIA INQUIRIES
Carl-Johan Dalsgaard, CEO of RSPR Pharma AB
Phone +46 709 759 863
Mail: carl-johan.dalsgaard@healthcap.eu
www.rsprpharma.com
About HealthCap
HealthCap is a European venture capital firm investing solely and globally in life sciences. It is one of the larger VC’s within life sciences in Europe, having raised more than EUR 1 billion in seven funds since 1996, invested in 103 companies and taken 37 companies public. HealthCap has over the years backed and built companies developing new treatments for people with life-altering conditions. HealthCap’s investment strategy focuses on diseases with high unmet medical needs and therapies that have the potential to be transformative and change medical practice and the lives of patients suffering these conditions. Over the years the portfolio companies have developed 22 pharmaceutical products to the market. Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies helping patients with life-threatening diseases to live better lives. In addition, HealthCap companies have brought more than forty medical device products to market, including innovative treatments such as CoreValve®, Zephyr® and Cerament-G®. These products have generated significant value to many stakeholders, including patients, physicians, society as well as to HealthCap’s investors.
For further information visit www.healthcap.se
About Novo A/S
Novo A/S, the holding company in the Novo Group, is responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than USD 30 billion. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science and biotechnology, as well as manages a broad portfolio of financial assets.
For further information visit www.novo.dk
About Forbion Capital Partners
Forbion Capital Partners is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. Forbion invests in life sciences companies in the pharmaceutical, as well as the medical device space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in multiple companies. With the new fund FCFIII, Forbion manages well over €700 Million across six funds. Its investors include the EIF through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion also operates a joint venture with BioGeneration Ventures, who manages two separate seed and early stage funds focused on Benelux.
For further information visit www.forbion.com
About Sunstone Capital
Sunstone Capital is an independent venture capital investor founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Capital focuses on developing and expanding early-stage Life Science and Technology companies with strong potential to achieve global success in their markets. Sunstone Capital currently manages four Life Science funds and three Technology funds. Within Life Science, Sunstone Life Science Ventures has invested in more than 40 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed several successful exits and IPOs. Managing total funds of EUR 700 million, Sunstone Capital is one of the largest and most active European venture capital investors.
For further information visit www.sunstone.eu
Source: RSPR_Pharma_Hires_CBO_2016-08-23
